Adicet Bio Inc.

www.adicetbio.com

High-Tech Company
Public Company

(NASDAQ GM: ACET)

TECH VERTICALS

Biologicals, Biotechnology, Cancer, Life Sciences, MedTech

General Data

Sector	Biomed
Company Stage:	R&D
Established	2014
Number of Employees	150
Reg. Number:	abCDe

DESCRIPTION

Adicet Bio is a clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies (uICT). Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

TECHNOLOGY

Adicet is engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptors (TCRs) directed to either tumor-specific cell surface or intracellular targets in order to enable the precise engagement and killing of tumor cells. Adicet intends to generate multiple clinical product candidates for various hematological and solid tumor cancers, and other diseases.

Products and Phases

Product	Phase
ADI-001	Phase I
ADI-001 is a first-in-class investigational allogeneic gamma delta CAR T cell therapy currently being developed in autoimmune indications. Currently in a Phase 1 study in lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). In June 2024, the FDA granted ADI-001 Fast Track Designation for the potential treatment of relapsed/refractory class III or class IV LN.
ADI-212	IND-Enabling
ADI-212 targets PSMA (gene-edited w/ armor), for treating Metastatic Castration-Resistant Prostate Cancer (mCRPC).

	TARGET MARKETS
	Healthcare Providers, Patients suffering from Cancer and Viral Diseases.

	BUSINESS MODEL
	B2B

CONTACT INFO

Expand / Collapse All

Main Address: Redwood City, United States

Address	1000 Bridge Parkway
City	Redwood City
State/Province	CA
Country	United States
Zip	94065

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Boston, United States

Address	131 Dartmouth St., 3rd Floor
City	Boston
State/Province	MA
Country	United States
Zip	02116

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Chen Schor	CEO & President	resTORbio (CEO)
Dr. Blake Aftab	Chief Scientific Officer
Dr. Julie Maltzman	Chief Medical Officer
Mr. Nick Harvey	CFO
Dr. Don Healey	CTO
Ms. Amy Locke	CHRO
Dr. Aya Jakobovits	Founder	OrbiMed Israel (Venture Partner)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Board Member	Former EVP, Clinical Medicine & External Innovation, Vertex Pharmaceuticals
abC Defghij	Board Member	Principal, SDA Ventures LLC
abC Defghij	Board Member	Former VP, Corporate Development Pharmaceuticals, Johnson & Johnson
abC Defghij	Board Member	CEO, Versanis Bio
abC Defghij	Board Member	Chief Commercial Officer, Denali Therapeutics Inc.
abC Defghij	Board Member	Director, President & CEO, Adicet Bio
abC Defghij	Board Member	Partner & Portfolio Manager, Abingworth LLP

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Reverse Merger

Sep. 15, 2020

R&D

abCDe

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Dec. 10, 2021	Third Public Offering	NASDAQ GM	abCDe	abCDe	Including the exercise in full of the underwriters' option to purchase additional shares ($13m).
Feb. 16, 2021	Second Public Offering		abCDe	abCDe	Including the exercise in full of the underwriters' option to purchase additional shares ($17.5m)

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Second Round

Oct. 02, 2019

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Corporate VC	abCDe
abC Defghij	Corporate VC	abCDe
abC Defghij	Corporate VC	abCDe
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	High-Tech Company	abCDe
abC Defghij	Traditional Industry	abCDe	Via OCI Enterprises, Inc, the North American subsidiary under OCI Company Ltd.
abC Defghij	High-Tech Company	abCDe

First Round - Extended

Jan. 27, 2016

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Corporate VC	abCDe

First Round

Aug. 25, 2015

R&D

abCDe

	Acquisitions made by Adicet Bio

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Biomed...	Oct. 14, 2015	abCDe

Last Updated:	abCDe
IVC Number:	abCDe